Clinical Trial Update: Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma [Phase 3]

View source ↗

Summary

A Phase 3 study of AP-12009 in recurrent or refractory anaplastic astrocytoma or secondary glioblastoma was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• AP-12009

Snippet

Sponsor: Isarna Therapeutics GmbH | Conditions: Anaplastic Astrocytoma, Glioblastoma | Phase 3 | Status: TERMINATED | Results posted: 2014-08-22